Objective:

To study the safety and effectivity of ultrasound-guided microwave ablation combined lauromacrogol injection technology for the symptomatic uterine leiomyomas.

Methods:

14 patients with 14 symptomatic uterine leiomyomas ac-cepted the therapy of microwave ablation combined with lauromacrogol injection technology. T

he size of uterine leiomyomas was measured by ultrasound after 1 month

3 months

6 months and 1 year. And the clinical symptoms before and after the treatment were compared.

Results:

The changes of the size of uterine leiomyomas and the level of hemoglobin were observed in 14 patients after 1 month

3 months

6 months

1 year. The results showed that the clinical symptoms of all patients were improved in different degree. All patients had no adverse reactions and complications during and after treatment. The averaged volume of uterine leiomyomas be-fore treatment

1 months after treatment

3 months after treatment

6 months after treatment

1 year after treatment was (53.3220.18)

(27.5310.55)

(11.734.40)

(8.493.53)

and (3.751.40)cm 3

respectively. The degree of uterine leiomyomas decreased was (479)%

(775)%

(835)%

(932)%

respectively.

Conclusion:

The treatment of microwave ablation combined lauromacro-gol injection technology for the symptomatic uterine leiomyomas was a good treatment after the follow-up observation. It can avoid the risk of the microwave treatment and improve the curative effect. It has a good application prospect and popularization value.